Akaal Pharma Pty Ltd to develop First-in-Class topical treatment for pruritus in inflammatory skin diseases
Melbourne, Australia, 3rd June 2021. Akaal Pharma Pty Limited (Akaal Pharma) today announced that it is developing novel multimodal action Spingosine-1-Phosphate receptor subtype-1 (S1P1) modulator and lead topical drug candidate “AKP-11” for pruritus and inflammation. AKP-11 downmodulate the cytokines implicated in pruritic skin diseases and was safe and well tolerated in two of our Phase-1 … Read more